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Conclusion: The experimentally determined RSP of the liquid 
fiducial marker was in good agreement (within 1%) of the 
theoretical calculation. The investigated liquid fiducial 
marker introduced smaller dose perturbation than the solid 
fiducial markers. The liquid fiducial marker shows promise 
for use in image-guided proton therapy of locally advanced 
lung cancer, as the risk of altering the clinical dose 
distribution is minimal. 
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Purpose or Objective: The purpose of this study is to 
investigate about feasibility of using volumetric modulated 
arc therapy (VMAT) technique to provide a Grid dose 
distribution with the therapeutic ratio (TR) advantage similar 
to the block-based Grid.  
 
Material and Methods: A series of cylinders with hole 
diameters of 1.3 cm and 1 cm height was created in a 
phantom as the boost volume within a larger volume target. 
The Monaco® 5 treatment planning system was used to plan 
the phantom. Four arcs, with collimator angles at 00 and 180 
0 were used. The cost functions were defined to deliver 17 
Gy dose to the boost volume and 6 Gy dose to the target 
volume. A dose profile from treatment plan was utilized to 
calculate TR for the VMAT-based Grid. In addition, for an 
available Grid block in our department the TR value was 
calculated from dose profile using EBT Gafchromic film. The 
Hug–Kellerer (H-K) radiobiological model (Equation 1) which 
is more appropriate at doses higher than 12 Gy was used to 
calculate survival fraction of cell lines under a single hole of 
the both Grids. The values of α/β ratios for tumor cells and 
normal cells were considered to be 10 Gy and 2.5 Gy, 
respectively. 
Equation 1: 
 
Where the Vi represents the relative cell numbers receiving 
the same dose ranging from Di and Di+1. The therapeutic 
advantage of the Grid irradiation was considered in terms of 
the normal tissue cell survival ratio (Grid/open ﬁeld ratio) for 
the same tumor cell survival. The therapeutic ratio (TR) was 
calculated for both VMAT-based and block-based Grids. 
 
Results: Figure 1 shows a 2D dose distribution of VMAT-based 
and block-based Grids at the center of the phantom. The 
VMAT plan generated a highly spatially modulated dose 
distribution in the volumes. D95% and D50% for the cylinders 
and the target in Gy were 16.5, 17 and 6, 10 respectively. 
The valley to peak ratio of the VMAT-based and block-based 
Grid was 19% and 22% respectively. The Therapeutic ratio for 
VMAT-based and block-based Grid was obtained 1.25 and 1.38 
respectively. 
 
 
 
Figure 1-The beam proﬁle for (a) the VMAT-based Grid and 
(b) the block-based Grid. Dose distributions of (c) VMAT-
based Grid from treatment plan and (d) block-based Grid 
from EBT Gafchromic film. 
 
Conclusion: The therapeutic ratio value obtained for VMAT-
based Grid demonstrated the feasibility of volume arc 
therapy to deliver spatially fractionated radiation therapy 
technique which can help the treatment time with the 
additional potential advantage of reducing dose to the 
normal tissues. 
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Purpose or Objective: This study provides a comprehensive 
overview of our geometric accuracy of frameless, linac-based 
intracranial SRS treatments. It is currently used to evaluate 
and further improve SRS treatment accuracy at our institute. 
Moreover, for other institutes, the overview may be used as 
reference material to supplement the more coarsely defined 
tolerance limits available in guidelines. To our knowledge, 
this is the first study that presents an overview of MRI/CT-to-
RT treatment accuracies in such detail, combining regular QA 
data with clinical data, for a specific treatment.  
 
Material and Methods: Our intracranial SRS treatments are 
based on a non-coplanar dual arc VMAT technique (table 0º 
and ±90º), in combination with an extensive online IGRT 
protocol with table correction verification and a post 
treatment CBCT. We systematically evaluated precision of 
the main elements of this SRS chain. We gathered patient set 
up data and image registration data, evaluated the imaging, 
treatment planning and QA protocols that were used, 
measured small fields (≤3 cm²) and compared this data with 
the TPS beam fit, and analysed QA data of the last couple of 
